The Brigham and Women's Hospital; Inc.;The Brigham and Womens Hospital
发明人:
LEE, Richard T.
申请号：
ES16158762
公开号：
ES2685697T3
申请日:
2003.05.09
申请国别(地区):
ES
年份:
2018
代理人:
摘要：
An agent that is an anti-inflammatory agent, an antithrombotic agent, an antiplatelet agent, a fibrinolytic agent, a lipid reducing agent, a direct thrombin inhibitor, a glycoprotein IIb / IIIa receptor inhibitor, an agent that binds to Cell adhesion molecules and inhibit the ability of white blood cells to bind to cell adhesion molecules, a calcium channel blocker, a beta-adrenergic receptor blocker, a cyclooxygenase-2 inhibitor or a system inhibitor renin-angiotensin (RAS), for use in a method to treat a subject to reduce the risk of a cardiovascular condition that develops in the subject, in which the cardiovascular status is selected from heart failure and myocardial infarction, and in the that the subject is identified using an in vitro method comprising: obtaining a level of soluble IL1RL-1 protein in a biological sample of the subject； compare the level of soluble IL1RL-1 protein with a single predetermined cut-off value specific for the diagnosis of heart failure or myocardial infarction； in which a level of soluble IL1RL-1 protein equal to or greater than the single predetermined cut-off value is indicative of whether the subject will benefit from treatment with the agent.Un agente que es un agente antiinflamatorio, un agente antitrombótico, un agente antiplaquetario, un agente fibrinolítico, un agente reductor de lípidos, un inhibidor directo de la trombina, un inhibidor del receptor de la glicoproteína IIb/IIIa, un agente que se une a moléculas de adhesión celular e inhiben la capacidad de los glóbulos blancos para unirse a las moléculas de adhesión celular, un bloqueador de los canales de calcio, un bloqueador de los receptores beta-adrenérgicos, un inhibidor de la ciclooxigenasa-2 o un inhibidor del sistema renina-angiotensina (RAS), para uso en un método para tratar un sujeto para reducir el riesgo de una afección cardiovascular que se desarrolla en el sujeto, en el que el estado cardiovascular se selecciona de insuficiencia cardíaca e infarto de mioca
